• Je něco špatně v tomto záznamu ?

No Time Dependence of Ciprofloxacin Pharmacokinetics in Critically Ill Adults: Comparison of Individual and Population Analyses

M. Šíma, D. Michaličková, P. Ryšánek, P. Cihlářová, M. Kuchař, D. Lžičařová, J. Beroušek, JM. Hartinger, T. Vymazal, O. Slanař

. 2021 ; 13 (8) : . [pub] 20210727

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024303

Grantová podpora
LTAUSA-243018 Ministerstvo Školství, Mládeže a Tělovýchovy
PROGRES Q25/LF1 Univerzita Karlova v Praze
SVV 260523 Univerzita Karlova v Praze
A1_FPBT_2021_002 Specific university research

The aim of this prospective PK study was to evaluate the pharmacokinetics of ciprofloxacin dosed within the first 36 h (early phase) and after 3 days of treatment (delayed phase) using individual and population PK analysis. The secondary aim of the study was to evaluate possible dosing implications of the observed PK differences between early and delayed phases to achieve a PK/PD target for ciprofloxacin of AUC24/MIC ≥ 125. Blood concentrations of ciprofloxacin (1 and 4 h after dose and trough) were monitored in critically ill adults in the early and delayed phases of the treatment. Individual and population PK analyses were performed. Complete concentration-time profiles in the early phase, delayed phase, and both phases were obtained from 29, 15, and 14 patients, respectively. No systematic changes in ciprofloxacin PK parameters between the early and delayed phases were observed, although variability was higher at the early phase. Both individual and population analyses provided similar results. Simulations showed that after standard dosing, it is practically impossible to reach the recommended ciprofloxacin PK/PD target (AUC/MIC ≥ 125) for pathogens with MIC ≥ 0.5 mg/L. A dosing nomogram utilizing patients' creatinine clearance and MIC values was constructed. Both individual and population analyses provided similar results. Therapeutic drug monitoring should be implemented to safeguard the optimal ciprofloxacin exposure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024303
003      
CZ-PrNML
005      
20240522102904.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics13081156 $2 doi
035    __
$a (PubMed)34452118
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
245    10
$a No Time Dependence of Ciprofloxacin Pharmacokinetics in Critically Ill Adults: Comparison of Individual and Population Analyses / $c M. Šíma, D. Michaličková, P. Ryšánek, P. Cihlářová, M. Kuchař, D. Lžičařová, J. Beroušek, JM. Hartinger, T. Vymazal, O. Slanař
520    9_
$a The aim of this prospective PK study was to evaluate the pharmacokinetics of ciprofloxacin dosed within the first 36 h (early phase) and after 3 days of treatment (delayed phase) using individual and population PK analysis. The secondary aim of the study was to evaluate possible dosing implications of the observed PK differences between early and delayed phases to achieve a PK/PD target for ciprofloxacin of AUC24/MIC ≥ 125. Blood concentrations of ciprofloxacin (1 and 4 h after dose and trough) were monitored in critically ill adults in the early and delayed phases of the treatment. Individual and population PK analyses were performed. Complete concentration-time profiles in the early phase, delayed phase, and both phases were obtained from 29, 15, and 14 patients, respectively. No systematic changes in ciprofloxacin PK parameters between the early and delayed phases were observed, although variability was higher at the early phase. Both individual and population analyses provided similar results. Simulations showed that after standard dosing, it is practically impossible to reach the recommended ciprofloxacin PK/PD target (AUC/MIC ≥ 125) for pathogens with MIC ≥ 0.5 mg/L. A dosing nomogram utilizing patients' creatinine clearance and MIC values was constructed. Both individual and population analyses provided similar results. Therapeutic drug monitoring should be implemented to safeguard the optimal ciprofloxacin exposure.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Michaličková, Danica $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
700    1_
$a Ryšánek, Pavel $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
700    1_
$a Cihlářová, Petra $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, 166 28 Prague, Czech Republic
700    1_
$a Kuchař, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, 166 28 Prague, Czech Republic
700    1_
$a Lžičařová, Daniela $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Beroušek, Jan $u Department of Anesthesiology and ICM, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Hartinger, Jan $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $7 xx0224709
700    1_
$a Vymazal, Tomáš $u Department of Anesthesiology and ICM, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 8 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34452118 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20240522102900 $b ABA008
999    __
$a ind $b bmc $g 1708271 $s 1144800
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 8 $e 20210727 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a LTAUSA-243018 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a PROGRES Q25/LF1 $p Univerzita Karlova v Praze
GRA    __
$a SVV 260523 $p Univerzita Karlova v Praze
GRA    __
$a A1_FPBT_2021_002 $p Specific university research
LZP    __
$a Pubmed-20211006
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace